Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
1. Primary objective: To assess perception of daily and weekly variability of symptoms in stable GOLD C and D COPD patients and their impact on daily life activities
2. Secondary objectives:
* To describe the current treatment practice for the management of GOLD C and D COPD in MEA countries and their adherence to the GOLD 2015 guidelines
* To compare patients' perception of symptoms variability and their impact on activities between Gold categories C and D
* To identify demographic, behavioral and clinical factors associated with symptoms variability.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients eligible for inclusion have to fulfill all of the following criteria:
1. Stable GOLD C or D COPD patient under maintenance treatment, over 45 years, who provided signed informed consent;
2. COPD diagnosis documented by spirometry performed in the past 12 months with an FEV1/FVC \< 0.7 and an FEV1 \< 50% predicted.
You may not be if
1. Patient with an ongoing COPD exacerbation\*;
2. Patient who has experienced an exacerbation\* in the previous 3 months;
3. History of asthma, allergic rhinitis, lung cancer or any other significant respiratory disease, such as tuberculosis, lung fibrosis or sarcoidosis;
4. Inability to understand the study related questions;
5. Mentally disabled patient or unable to read and write;
6. Pregnant.
7. Current participation in a clinical trial;
Clareo Health | A Cross-sectional Study of COPD and Symptom Variability in MEA Countries
